419 [18F]FDG uptake and expression of immunohistochemical markers 8 Table 1. Baseline characteristics TN FP TP n=8 n=8 n=8 p Female 6 (75%) 5 (63%) 5 (63%) 0.83a Age (years) (mean ± SD) 51.2 ± 12.3 54.0 ± 11.8 54.2 ± 20.3 0.91b Nodule size on histopathology, mm (median, IQR) 33 (25-45) 26 (21-43) 35 (21-44) 0.83c Thyroid function TSH, mU/L (median, IQR) 1.20 (0.46-2.05) 1.65 (0.98-2.80) 1.55 (1.18-1.75) 0.21c fT4, pmol/L (median, IQR) 16.1 (13.6-17.4) 14.1 (13.3-15.5) 13.8 (12.0-19.8) 0.53c [18F]FDG-PET/CT scan SUVmax (g/mL) (median, IQR) 2.1 (1.2-2.3) 7.0 (4.5-31.0) 11.1 (4.2-20.8) <0.001c,d SUVpeak (g/mL) (median, IQR) 1.7 (1.0-2.1) 4.8 (4.0-24.6) 9.6 (2.8-15.8) 0.002c,d SUVmax ratio (median, IQR) 1.0 (0.8-1.2) 4.3 (2.3-14.3) 6.2 (1.6-14.0) <0.001c,d Histopathological diagnosis Hyperplastic nodule 4 (50%) 2 (25%) Follicular adenoma 4 (50%) 4 (50%) Hürthle cell adenoma 2 (25%) PTC 2 (25%) FVPTC 1 (12.5%) FTC, minimally invasive 3 (37.5%) HCC, minimally invasive 2 (25%) TNM stage T1a 0 (0%) T1b 2 (25%) T2 4 (50%) T3 2 (25%) N0/x 6 (75%) N1a 2 (25%) FP, false-positives. FTC, follicular thyroid carcinoma. FVPTC, follicular variant PTC. HCC, Hürthle cell carcinoma. IQR, interquartile range. PTC, papillary thyroid carcinoma. SD, standard deviation. TN, true-negatives. TP, true-positives. a: Pearson’s chi-squared. b: one-way ANOVA. c: Kruskall-Wallis test. d: post hoc analysis: SUV max p=0.001* between TN and FP groups, p<0.001* between TN and TP groups, and p=0.89 between FP and TP groups; SUVpeak p=0.003* between TN and FP groups, p=0.001* between TN and TP groups, and p=0.83 between FP and TP groups; SUVmax ratio p=0.001* between TN and FP groups, p<0.001* between TN and TP groups, and p=0.89 between FP and TP groups.
RkJQdWJsaXNoZXIy MTk4NDMw